Payment overview · 2025
General Payments
$834.66
44 reported records · 21 companies
Healthcare provider profile · identity verified
Analee Fish, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · REXBURG, ID · NPI 1407405111
Verified facts
What the public records show
CMS Open Payments records show Analee Fish, FNP received $834.66 in general payments during 2025 across 44 reported records.
ABBVIE INC. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.98 | 16.6% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.74 | 12.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.79 | 11.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.30 | 6.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.65 | 5.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.92 | 4.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.68 | 4.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.92 | 4.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $32.83 | 3.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.16 | 3.9% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $27.93 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.06 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.00 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.19 | 2.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $21.87 | 2.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.22 | 2.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.39 | 2.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.62 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.39 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.58 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.44 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $834.66 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $101.74 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $95.79 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.99 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $79.78 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.30 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.99 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.99 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.65 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.68 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.92 | 1 | 2025 |
Source payment records
|
|||||
| ELFABRIO Normalized: elfabrio |
Drug | Chiesi USA, Inc. | $32.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.06 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 111 | 38 |
| Lisinopril | Lisinopril | 77 | 22 |
| Metformin Hcl | Metformin Hcl | 66 | 19 |
| Omeprazole | Omeprazole | 66 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 63 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 57 | 25 |
| Azithromycin | Azithromycin | 52 | 50 |
| Gabapentin | Gabapentin | 49 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 23 |
| Meloxicam | Meloxicam | 44 | suppressed |
| Simvastatin | Simvastatin | 43 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 15 |
| Cephalexin | Cephalexin | 40 | 35 |
| Clonazepam | Clonazepam | 40 | 12 |
| Losartan Potassium | Losartan Potassium | 38 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Prednisone | Prednisone | 31 | 28 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Furosemide | Furosemide | 29 | 15 |
| Ozempic | Semaglutide | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 16 | 11 |
| Famotidine | Famotidine | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 14 |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $834.66 · 44 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, DAYBUE, ELFABRIO, FANAPT, GEMTESA, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN Access System, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error